scorecardresearch
Add as a preferred source on Google
Wednesday, November 12, 2025
TopicAstraZeneca

Topic: AstraZeneca

AstraZeneca, eBay to Tropicana — the 5 worst corporate PR blunders of 2020

Many of the corporate crises were self-inflicted. As in years past, executives often failed to apply the most basic principles of crisis and reputation management.

Argentina approves AstraZeneca-Oxford Covid vaccine for emergency use

The vaccine was given approval for emergency use over the course of the next year, accoarding to a statement by Argentina’s health regulator ANMAT.

UK approves AstraZeneca-Oxford Covid vaccine for emergency use

The vaccine will be prioritised for the country’s most vulnerable groups. It’s the second Covid vaccine to be cleared for emergency use in the UK after Pfizer and BioNTech.

UK poised to approve AstraZeneca Covid shot as need for vaccines grows

The go-ahead would come about three weeks after the UK became the first western country to begin vaccinations, using a shot from Pfizer and BioNTech.

UK says Oxford vaccine review ongoing, won’t be approved until safety, efficacy standards met

UK's Medicines and Healthcare products Regulatory Agency tells ThePrint vaccine review includes poring over pages of lab data. If cleared, it will likely boost chances of the vaccine's approval in India.

AstraZeneca plans post-Covid growth with $39 billion deal with Alexion Pharmaceuticals

The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of the Cambridge-based drugmaker.

AstraZeneca to test if combination of its Covid vaccine with Russia’s Sputnik V works better

Based on a monkey-adenovirus vector, AstraZeneca’s vaccine reported average effectiveness of 70%. Sputnik is the only Covid vaccine to use two different human-adenovirus vectors.

Approval, pricing, distribution — 5 questions India faces before rolling out Covid vaccine

3 firms have applied for emergency use approval, but no clarity yet on if people will get to choose a vaccine, or what the state’s role in procurement will be.

How AstraZeneca can recover from its Covid vaccine stumble

Even without a new trial, AstraZeneca can regain confidence in its research and vaccine – which still seems to show great promise – by releasing more granular data.

Alleging serious side-effects, vaccine trial participant seeks Rs 5 cr from Serum Institute

Chennai-based participant also sends legal notice to ICMR, DCGI, AstraZeneca & Oxford University to stop testing, manufacturing & distributing vaccine.

On Camera

This era has made journalistic independence harder than ever: New York Times publisher

Journalist Arthur Gregg Sulzberger delivered the Reuters Memorial Lecture on 4 March last year.

India’s factory data may get reality check in MoSPI’s new IIP plan, defunct factories to be dropped

MoSPI proposes to remove closed factories from IIP sample, aiming for truer picture of India’s industrial health in upcoming 2022–23 base series. Plan open to public feedback until 25 November.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Bihar is where politics moves, and everything else stands still

Bihar is blessed with a land more fertile for revolutions than any in India. Why has it fallen so far behind then? Constant obsession with politics is at the root of its destruction.